Recent advances of kinesin motor inhibitors and their clinical progress

Reviews on Recent Clinical Trials

Volumn 6, Issue 3, 2011, Pages 271-277

  Voultsiadou, Antiopi ^a   Sarli, Vasiliki ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Antimitotics; Ispinesib; KSP kinesin; Mitotic kinesins; Neoplasms; Taxanes; Tubulin targeting agents

Indexed keywords

ANTIMITOTIC AGENT; ARRY 520; AZD 4877; DOCETAXEL; EMD 534085; GSK 923295; ISPINESIB; KINESIN; LITRONESIB; MK 0731; PACLITAXEL; PROTEIN INHIBITOR; SB 743921; TAXANE DERIVATIVE; TUBULIN MODULATOR; UNCLASSIFIED DRUG; VINCA ALKALOID;

BLADDER CANCER; BREAST CANCER; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; NEOPLASM; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

ANTIMITOTIC AGENTS; ANTINEOPLASTIC AGENTS; CHROMOSOMAL PROTEINS, NON-HISTONE; CLINICAL TRIALS AS TOPIC; HUMANS; KINESIN; MICROTUBULES; NEOPLASMS; TUBULIN MODULATORS;

EID: 80051775132     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488711796575522     Document Type: Review

References (67)

1. Crown J, O'Leary M. The taxanes: an update. Lancet 2000; 355: 1176-1178.
2. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107-117.
3. Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001; 1: 370-377.
4. Miki H. Setou M, Kaneshiro K, Hirokawa N. All kinesin superfamily protein, KIF, genes in mouse and human. Proc Natl Acad Sci USA 2001; 98: 7004-7011.
5. Kashina AS, Baskin RJ, Cole DG, Wedman KP, Saxton WM, Scholey JM. A bipolar kinesin. Nature 1996; 379: 270-272.
6. Kozielski F, Sack S, Marx A, Thormählen M, Schönbrunn E, Biou V, Thompson A, Mandelkow EM, Mandelkow E. The crystal structure of dimeric kinesin and implications for microtubuledependent motility. Cell 1997; 91: 985-994.
7. Kapitein LC, Peterman EJ, Kwok BH, Kim JH, Kapoor TM, Schmidt CF. The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 2005; 435: 114-118.
8. Cameron LA, Yang G, Cimini D, Cancan JC, Kisurina-Evgenieva O, Khodjakov A, Danuser G, Salmon ED. Kinesin 5-independent poleward flux of kinetochore microtubules in PtK1 cells. J Cell Biol 2006; 173: 173-179.
9. Kapoor TM, Lampson MA, Hergert P, Cameron L, Cimini D, Salmon ED, McEwen BF, Khodjakov A, Chromosomes can congress to the metaphase plate before biorientation. Science 2006; 311: 388-391.
10. Kim Y, Heuser JE, Waterman CM, Cleveland DW. CENP-E combines a slow, processive motor and a flexible coiled coil to produce an essential motile kinetochore tether. J Cell Biol 2008; 181: 411-419.
11. Yao X, Abrieu A, Zheng Y, Sullivan KF. Cleveland DW. CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint. Nature Cell Biol 2000; 2: 484-1.
12. Tanudji M, Shoemaker J, L'Italien L, Russell L, Chin G, Schebye XM. Gene silencing of CENP-E by small interfering RNA in HeLa cells leads to missegregation of chromosomes after a mitotic delay. Mol Biol Cell 2004; 15: 3771-3781.
13. Hegde PS, Cogswell J, Carrick K, et al. Differential gene expression analysis of kinesin spindle protein in human solid tumors. Proc Am Soc Clin Oncol 2003; 22: 535.
14. Carter BZ, Mak DH, Shi Y, et al. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell Cycle 2006; 5: 2223-2229.
15. Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene 2003; 22: 3952-3963.
16. Castillo A, Morse III HC, Godfrey VL, Naeem R, Justice MJ. Overexpression of Eg5 causes genomic instability and tumor formation in mice. Cancer Res 2007; 67: 10138-10147.
17. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009; 4606(7252): 278-282.
18. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999; 286: 971-974.
19. Yan Y, Sardana V, Xu B, et al. Inhibition of a mitotic motor protein: where, how, and conformational consequences. J Mol Biol 2004; 335: 547-554.
20. Gartner M, Sunder-Plassmann N, Seiler J, et al. Development and Biological Evaluation of Potent and Specific Inhibitors of Mitotic Kinesin Eg5. Chem Bio Chem 2005; 6: 1173-1177.
21. Sarli V, Huemmer S, Sunder-Plassmann N, Mayer TU, Giannis A. Synthesis and biological evaluation of novel EG5 inhibitors. Chem Bio Chem 2005; 6: 2005-2013.
22. Brier S, Carletti E, DeBonis S, Hewat E, Lemaire D, Kozielski F. The marine natural product adociasulfate-2 as a tool to identify the MT-Binding region of kinesins. Biochemistry 2006; 45: 15644-15653.
23. Nakazawa J, Yajima J, Usui T, Ueki M, Takatsuki A, Imoto M, Toyoshima YY, Osada H. A novel action of terpendole E on the motor activity of mitotic Kinesin Eg5. Chem Biol 2003; 10: 131-137.
24. Hotha S, Yarrow JC, Yang JG, et al. HR22C16: a potent smallmolecule probe for the dynamics of cell division. Angew Chem Int Ed Engl 2003; 42: 2379-2382.
25. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004; 64: 3276-3280.
26. Cox CD, Breslin MJ, Mariano BJ, Coleman PJ, Buser CA, Walsh ES, Hamilton K, Huber HE, Kohl NE, Torrent M, Yan Y, Kuo LC, Hartman GD. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP. Bioorg Med Chem Lett 2005; 15: 2041-2045.
27. DeBonis S, Skoufias D, Robin G, et al. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol. Cancer Ther 2004; 3: 1079-1090.
28. Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005; 8: 49-59.
29. Parrish CA. Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem 2007; 50: 4939-4952.
30. Luo L. ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 2007; 3: 722-726.
31. Rickert KW. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP. Arch Biochem Biophys 2008; 469: 220-231.
32. Roecker AJ, Coleman PJ. Kinesin spindle protein (KSP) inhibitors. Part8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP. Bioorg & Med Chem Lett 2007; 17: 5677-82.
33. Sarli V, Giannis A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 2008; 1; 14(23): 7583-7587.
34. Liu M, Yu H, Huo L, Liu J, Li M, Zhou J. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor. Biochem Pharmacol 2008; 76: 169-178.
35. Shi J, Orth JD, Mitchison T. Cell Type Variation in Responses to Antimitotic Drugs that Target Microtubules and Kinesin-5. Cancer Res 2008; 68: 3269-3276.
36. Johnson RK, McCabe FL, Cauder E, et al. SB-715992, a Potent and Selective Inhibitor of KSP Mitotic Kinesin, Demonstrates Broad-spectrum Activity in Advanced Murine Tumors and Human Tumor Xenografts. Proc Am Assoc Cancer Res 2002; 43: 269.
37. Burris HA, Lorusso P, Jones S, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8,15 q 28 days. J Clin Oncol 2004; 22: 2078.
38. Heath EI, Alouisi A, Eder JP, et al. Phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3of a 21-day cycle in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2006; 24: 20-26.
39. Chu QS, Holen KD, Rowinsky EK, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. Proc Am Soc Clin Oncol 2004; 22: A2078.
40. Lee CW. Phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 2008; 26: 249-255.
41. Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs. 2008; 26: 265-72.
42. Shahin MS, Braly P, Rose PM, et al. A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer. ASCO Annual Meeting Proceedings Part I 2007; 25: (18S): abstr 5562.
43. El-Khoueiry AB, Iqbal S, Singh DA, et al. A randomized phase II non-comparative study of Ispinesib given weekly or every three weeks in metastatic colorectal cancer. 2006. In: ASCO Annual Meeting Proceedings; 2006: A California Cancer Consortium Study (CCC-P). Part I 24(18S); abstr 3595.
44. Beekman KW, Dunn R, Colevas D, et al. University of Chicago Consortium phase II study of ispinesib (SB-715992) inpatients (pts) with advanced renal cell carcinoma (RCC). 2007. In: ASCOAnnual Meeting Proceedings Part I; 2007: 25(18S): abstr 15573.
45. Tang PA, Siu LL, Chen EX, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008; 26: 257-264.
46. Beer TM. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer 2008; 6: 103-109.
47. Davis DA, Sarkar SH, Hussain M. Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 2006; 6: 22.
48. Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K, Kato H, Nishiwaki Y, Saijo N. Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Lung Cancer 2006; 54: 217-225.
49. Miller K, Ng C, Ang P, et al. Phase II, open label study of SB- 715992 (Ispinesib) in subjects with advanced or metastatic breast cancer. Breast Cancer Res Treat 2005; 94: (suppl 1):abstr 1089.
50. Purcell JW, Davis J, Reddy M, et al. Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer. Clin Cancer Res 2010; 15: 566-576.
51. Jones SF, Plummer ER, Burris HA, Razak AR, Meluch AA, Bowen CJ. Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2006; 24: 2027.
52. Rodon J, Till E, Patnaik A, Takimoto C, Beeram M, Williams D. Phase I study of ispinesib (SB-715992), a kinesin spindle protein inhibitor, in combination with capecitabine in patients with advanced solid tumors. Euro J Can 2006; 4: 193.
53. Blagden SP, Molife LR, Seebaran A, Payne M, Reid AHM, Protheroe AS. A phase I trial of ispinesib, a kinesin spidle protein inhibitor, with docetaxel in patients with advanced solid tumors. Br J Cancer 2008; 98: 894-899.
54. Holen KD, Belani CP, Wilding G, Ramalingam S, Heideman JL, Ramanathan RK, Bowen CJ, Williams DD, Hodge JP, Dar MM. Phase I study to determine tolerability and pharmacokinetics (PK) of SB-743921, a novel kinesin spindle protein (KSP) inhibitor. Proc Am Soc Clin Oncol 2006; 24: 2000.
55. Stein MN, Rubin EH, Scott PD, Fernandez R, Agrawal NG, Hsu K, Walker A, Holen K, Wilding G. Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731in cancer patients. Proc Am Soc Clin Oncol 2006; 24: 2001.
56. Lemieux C, DeWolf W, Voegtli W, et al. ARRY-520: a novel, highly selective KSP inhibitor with potent anti-proliferative activity. AACR Annual Meeting, 2007.
57. Woessner RD, Corrette C, Allen S, Hans J, Zhao Q, Aicher T. ARRY-520, a KSP inhibitor with efficacy and pharmacodynamic activity in animal models of solid tumors. AACR Meet Abstr 2007; 1433.
58. Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Trans Med 2009; 20: 7-63.
59. Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia 2009; 23: 755-762.
60. Woessner R, Tunquist B, Lemieux C, et al. ARRY-520, a Novel KSP Inhibitor with Potent Activity in Hematological and Taxaneresistant Tumor Models. Anticancer Res 2009; 29: 4373-4380.
61. Stephenson JJ, Lewis N, Martin JC, et al. Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2008; 26: 2516.
62. Putkey FR, Cramer T, Morphew MK, et al. Unstable kinetochoremicrotubule capture and chromosomal instability following deletion of CENP-E. Dev Cell 2002; 3: 351-365.
63. Pan J, Yeung SC. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 2005; 15, 65(20): 9109-9112.
64. Sakowicz R, Berdelis MS, Ray K, Blackburn CL, Hopmann C, Faulkner DJ, Goldstein LS. A marine natural product inhibitor of kinesin motors. Science 1998; 10 (280): 292-295.
65. Henderson MC, Shaw YJ, Wang H, et al. UA62784; a novel inhibitor of CENP-E kinesin-like protein. Mol Cancer Ther 2009; 8: 36-44.
66. Shaw AY, Henderson MC, Flynn G, et al. Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. J Pharmacol Exp Ther 2009; 331(2): 636-47.
67. Wood KW, Lad L. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci USA 2010; 30, 107 (13): 5839-5844.